Teva Falls Short On Challenge To Velphoro Formulation Patent
Israeli Firm Has A Second Case Pending, Although A Trial Date Is Not Set
Executive Summary
Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.